Hip OsteoarthritisMOVE-HIPNCT07839403
MOVE-HIP: Ceramic Hip Resurfacing Versus Total Hip Arthroplasty Using Activity Monitoring
A study testing Ceramic-on-Ceramic Hip Resurfacing Arthroplasty and Contemporary Total Hip Arthroplasty in people with Hip Osteoarthritis, run by Danderyd Hospital at 1 site in Sweden.
Trial summary
MOVE-HIP is a pragmatic, multicenter randomized clinical trial comparing ceramic hip resurfacing arthroplasty with contemporary total hip arthroplasty in adults with symptomatic hip osteoarthritis who are considered clinically eligible for both procedures. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hip Osteoarthritis
- What is being tested?
- Ceramic-on-Ceramic Hip Resurfacing Arthroplasty and Contemporary Total Hip Arthroplasty
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 220 participants
- Where
- 1 siteSweden
- Study dates
- 25 Sep 2026to 31 Dec 2039
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 18 years or older.
- Symptomatic hip osteoarthritis for which primary hip arthroplasty is indicated according to routine clinical practice.
- Considered suitable for both ceramic hip resurfacing arthroplasty and uncemented total hip arthroplasty by the treating surgeon.
- Ability and willingness to comply with study procedures, including patient-reported outcome measures, radiographs, registry linkage, and repeated wearable monitoring.
- Provision of written informed consent.
Who cannot join
- Anatomical or pathological conditions that clearly preclude hip resurfacing arthroplasty or total hip arthroplasty, including severe deformity requiring non-standard implants or techniques.
- Insufficient femoral head or acetabular bone quality, including large or multiple cysts, advanced femoral head necrosis, severe osteopenia, or osteoporosis where this would contraindicate hip resurfacing arthroplasty.
- Body mass index greater than 40 kg/m^2.
- Requirement for specialized implants outside routine study procedures.
- Medical comorbidity rendering the patient unfit for surgery.
- Cognitive impairment, severe psychiatric disease, alcohol or substance abuse, language barrier, or other reason judged to prevent informed consent or compliance with follow-up.
- Inability to complete patient-reported outcome measures or to participate in wearable monitoring.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Sweden1 site, 1 recruiting
- Recruiting
Danderyd Hospital
Danderyd, 182 88
Olof Sköldenberg, MD, PhD
About this study
Official title: A Pragmatic, Multicenter, Patient-Blinded, Preference-Tolerant Randomized Clinical Trial Comparing Ceramic Hip Resurfacing With Total Hip Arthroplasty Using Activity Monitoring
MOVE-HIP is a pragmatic, multicenter randomized clinical trial comparing ceramic hip resurfacing arthroplasty with contemporary total hip arthroplasty in adults with symptomatic hip osteoarthritis who are considered clinically eligible for both procedures. Participants in the randomized cohort are allocated 1:1 to either ceramic hip resurfacing or total hip arthroplasty and are kept blinded to treatment allocation where feasible through the 24-month primary follow-up.
The primary objective is to determine whether ceramic hip resurfacing results in greater objectively measured mean daily walking distance over the postoperative period from 3 to 24 months. Activity is assessed during standardized 7-day wearable monitoring periods at 3, 12, and 24 months. The primary estimand is the adjusted overall between-group difference across these postoperative time points. A parallel observational preference cohort may include otherwise eligible patients who decline randomization; this cohort is analyzed separately and does not contribute to the primary randomized inference.
Read the detailed description
The trial is designed to test whether a contemporary ceramic-on-ceramic hip resurfacing strategy provides a clinically meaningful advantage over modern total hip arthroplasty in real-world physical activity. Randomization is stratified by study site and sex. All participants undergo baseline assessment including patient-reported outcomes, radiographs, clinical data, and 7-day wearable activity monitoring before surgery.
The randomized cohort includes 220 participants, 110 per treatment group. Follow-up is planned at 3 months, 12 months, 24 months, 5 years, and 10 years. Secondary outcomes include walking distance at 24 months, daily step count, patient-reported outcomes, radiographic outcomes, perioperative outcomes, complications, reoperations, revisions, implant survival, and health-economic outcomes. The study is academically led, and the observational preference cohort follows the same assessment schedule but is analyzed separately.
- Conditions
- Hip Osteoarthritis
- Being tested
- Ceramic-on-Ceramic Hip Resurfacing Arthroplasty, Contemporary Total Hip Arthroplasty
- Keywords
- Hip Resurfacing Arthroplasty, Total Hip Arthroplasty, Ceramic-on-Ceramic, Physical Activity, Accelerometry, Wearable Activity Monitoring
- Medical subject headings
- Osteoarthritis, Hip, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ceramic-on-Ceramic Hip Resurfacing ArthroplastyProcedure or surgery
Also called H1 ceramic hip resurfacing
Cementless ceramic-on-ceramic hip resurfacing arthroplasty. The currently planned study implant is H1, or a subsequent equivalent generation if applicable. Procedures are performed by surgeons with documented arthroplasty experience and system-specific training.
Contemporary Total Hip ArthroplastyProcedure or surgery
Contemporary standard primary total hip arthroplasty using established implants and bearing combinations according to local routine and individual clinical assessment. Implant choice remains clinically appropriate for the individual participant.
| Study group | Role | What they receive |
|---|---|---|
| Ceramic Hip Resurfacing Arthroplasty | Experimental | Participants undergo cementless ceramic-on-ceramic hip resurfacing arthroplasty using the selected study system according to manufacturer instructions, surgeon training requirements, and local surgical routines. Receives: Procedure: Ceramic-on-Ceramic Hip Resurfacing Arthroplasty |
| Total Hip Arthroplasty | Active comparator | Participants undergo contemporary standard primary total hip arthroplasty using established implants and bearing combinations according to local routine and individual clinical assessment. Cementless fixation is expected in most cases where clinically appropriate. Receives: Procedure: Contemporary Total Hip Arthroplasty |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean Daily Walking Distance Over the Postoperative Period From 3 to 24 Months
Mean daily walking distance is assessed during standardized 7-day wearable monitoring periods at each postoperative time point. The primary estimand is the adjusted overall between-group difference in mean daily walking distance across 3, 12, and 24 months, with adjustment for preoperative walking distance and prespecified covariates.
Measured: 3, 12, and 24 months after surgery
Secondary outcomes (14)
Mean Daily Walking Distance at 24 Months
Mean daily walking distance derived from a standardized 7-day wearable monitoring period at 24 months.
Measured: 24 months after surgery
Mean Daily Step Count Over the Postoperative Period From 3 to 24 Months
Mean daily step count derived from standardized 7-day wearable monitoring periods at 3, 12, and 24 months.
Measured: 3, 12, and 24 months after surgery
Forgotten Joint Score-12 (FJS-12) at 24 Months
Joint awareness assessed using the Forgotten Joint Score-12 (FJS-12). Scores range from 0 to 100, with higher scores indicating less awareness of the operated joint during everyday activities and a better outcome.
Measured: 24 months after surgery
Proportion of Participants With FJS-12 Score of 80 or Higher
Proportion of participants achieving a Forgotten Joint Score-12 (FJS-12) of at least 80. The scale ranges from 0 to 100, with higher scores indicating less awareness of the operated joint during everyday activities and a better outcome.
Measured: 24 months after surgery
Hip Disability and Osteoarthritis Outcome Score (HOOS) Subscales
HOOS Pain, Symptoms, Activities of Daily Living, Sport/Recreation, and Quality of Life subscales at 24 months. Each subscale ranges from 0 to 100, with higher scores indicating better status.
Measured: 24 months after surgery
University of California, Los Angeles (UCLA) Activity Score
Self-reported habitual physical activity level assessed using the University of California, Los Angeles (UCLA) Activity Score. Scores range from 1 to 10, with higher scores indicating a higher level of physical activity and a better activity-related outcome.
Measured: 24 months after surgery
High-Activity Arthroplasty Score (HAAS)
Self-reported functional ability assessed using the High-Activity Arthroplasty Score (HAAS), covering walking, running, stair climbing, and activity level. Total scores range from 0 to 18, with higher scores indicating greater functional ability and a better outcome.
Measured: 24 months after surgery
EuroQol 5-Dimension (EQ-5D-5L Index)
Health-related quality of life assessed using the EQ-5D-5L questionnaire. Responses are converted into an index using the Swedish experience-based time trade-off value set (Burström et al., 2020). Index values range from approximately 0.243 to 0.975, with higher values indicating better health-related quality of life.
Measured: 24 months after surgery
EuroQol Visual Analogue Scale (EQ VAS)
Self-rated overall health assessed using the EuroQol Visual Analogue Scale (EQ VAS). Scores range from 0 (the worst health imaginable) to 100 (the best health imaginable), with higher scores indicating better perceived health.
Measured: 24 months after surgery
Radiographic Implant and Hip Biomechanics Outcomes
Radiographic assessment includes component orientation and fixation, radiolucent lines, migration or loosening, heterotopic ossification, leg length and offset where feasible. In the hip resurfacing group, femoral neck integrity, notching, narrowing, fracture, femoral head movement or crushing, and component alignment are additionally assessed.
Measured: 24 months after surgery
Adverse Events and Postoperative Complications
Incidence and type of adverse events and complications, including infection, dislocation, periprosthetic fracture, femoral neck fracture, implant fracture, thromboembolic events, nerve injury, wound complications, persistent pain, and other procedure- or implant-related events.
Measured: From surgery through 24 months
Reoperations and Revisions of the Index Hip
Number and proportion of participants undergoing reoperation or revision of the index hip, including reason and components exchanged or removed.
Measured: From surgery through 24 months
Health-Economic Outcomes
Quality-adjusted life years derived from EQ-5D and incremental cost-effectiveness comparing ceramic hip resurfacing with total hip arthroplasty over 24 months, using available direct and indirect cost data.
Measured: From surgery through 24 months
Long-Term Implant Survival
Revision-free implant survival assessed using study follow-up and registry data at 5 and 10 years.
Measured: 5 and 10 years after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Sep 2026
- Study start25 Sep 2026 (estimated)
- Primary completion31 Dec 2031 (estimated)
- Study completion31 Dec 2039 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hip OsteoarthritisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Two-arm randomized superiority trial. A parallel observational preference cohort may include otherwise eligible patients who decline randomization; the preference cohort is analyzed separately and is not part of the primary randomized comparison.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 220 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Danderyd Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Karolinska Institutet, Hässleholm Hospital, Ortopediskt Centrum
- Responsible party
- Principal investigator, Olof Skoldenberg, Karolinska Institutet
- Investigators
- Olof Sköldenberg, MD, PhD, Principal investigator, Danderyd Hospital, Region Stockholm / Karolinska Institutet
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07839403
- Sponsor's protocol ID
- MOVE-HIP
- Acronym
- MOVE-HIP
- Status last verified
- Sep 2026
- First submitted
- 16 Sep 2026
- Last updated
- 24 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Undecided as of yet pending IRB approval.